Evidence map›Paper›PMID 39677411›Full record

ArticleOncology letters2025

Network pharmacology and molecular docking reveal the mechanism of action of Bergapten against non‑small cell lung cancer.

Yihao Chen, Yu Fu, Hongbo Zou, Pingsong Wang, Yao Xu, Qichao Xie

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yihao ChenDepartment of Oncology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing 401120, P.R. China.
Yu FuDepartment of Oncology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing 401120, P.R. China.
Hongbo ZouDepartment of Oncology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing 401120, P.R. China.
Pingsong WangDepartment of Oncology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing 401120, P.R. China.
Yao XuDepartment of Oncology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing 401120, P.R. China.
Qichao XieDepartment of Oncology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing 401120, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality worldwide, necessitating new treatment approaches with minimal side effects. In the present study, the potential of Bergapten (5-methoxypsoralen), a natural furanocoumarin compound, as a therapeutic agent against NSCLC was investigated by using network pharmacology, molecular docking and

Indexed as

5-methoxypsoralencell senescencenon-small cell lung cancerPI3K/AKT

Identifiers

PMID39677411
PMCPMC11638938

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.